Serum Levels of Matrix Metalloproteinase (MMP) 9, a Risk Factor for Acute Coronary Syndrome, Are Reduced Independently of Serum MMP-3 by Anti-TNF-α Antibody (Infliximab) Therapy in Patients With Rheumatoid Arthritis

Serum Levels of Matrix Metalloproteinase (MMP) 9, a Risk Factor for Acute Coronary Syndrome, Are Reduced Independently of Serum MMP-3 by Anti-TNF-α Antibody (Infliximab) Therapy in Patients With Rheumatoid Arthritis

Matrix metalloproteinase 9 (MMP-9) is a risk factor for cardiovascular events. The serum MMP-9 levels were measured before and 2 weeks after treatment with infliximab (3 mg/kg) in 12 rheumatoid arthritis (RA) patients. The serum average MMP-9 level was 238.5 ng/ml before treatment with infliximab in...

Full description

Bibliographic Details
Main Authors: Takuya Kotani, Tohru Takeuchi, Shinji Takai, Shuzo Yoshida, Kenichiro Hata, Koji Nagai, Daisuke Wakura, Kentaro Isoda, Shigeki Makino, Toshiaki Hanafusa
Format: Article
Language:English
Published: Elsevier 2012-01-01
Series:Journal of Pharmacological Sciences
Online Access:http://www.sciencedirect.com/science/article/pii/S1347861319304645

Internet

http://www.sciencedirect.com/science/article/pii/S1347861319304645

Similar Items